Can a new PET tracer spot tumors more clearly?

NCT ID NCT07776899

NEW Recruiting now Diagnosis Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Aug 20, 2026 · Last updated Aug 20, 2026

Summary

This trial is testing two new PET imaging tracers, FAPI-RuiJ and FAPI-04, to see how well they detect, stage, and monitor various solid tumors. The study will compare the diagnostic accuracy of these tracers against standard methods in 200 adults with suspected or confirmed tumors. The goal is to find a more precise imaging tool for cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAPI-RuiJ and FAPI-04, two FAP-targeted radiotracers for PET imaging
What this could lead to: If successful, this could provide a more accurate imaging tool to detect, stage, and monitor solid tumors, potentially improving cancer care.
What could go wrong: This is an early-stage diagnostic study, and the new tracer may not prove more accurate than existing methods. There are also risks from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.